Status:
COMPLETED
Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy
Lead Sponsor:
Far Eastern Memorial Hospital
Conditions:
Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer
Eligibility:
FEMALE
20+ years
Brief Summary
The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally give...
Eligibility Criteria
Inclusion
- women aged 20 and above with FIGO stage II-IV advanced ovarian, fallopian tube or primary peritoneal cancer who received debulking surgery, followed by either triweekly intravenous chemotherapy with bevacizumab or intraperitoneal chemotherapy; women who received neoadjuvant chemotherapy followed by interval debulking surgery were also eligible for participation. Intraperitoneal chemotherapy was defined as having one or more cycles of an intraperitoneal regimen administered.
Exclusion
- women who quit half-way or received chemotherapy at other site
Key Trial Info
Start Date :
June 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT05410938
Start Date
June 6 2022
End Date
May 1 2023
Last Update
July 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan, 22050